RadNet (RDNT) Projected to Post Quarterly Earnings on Monday

RadNet (NASDAQ:RDNT) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect RadNet to post earnings of $0.19 per share and revenue of $515.6660 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 10:30 AM ET.

RadNet Stock Performance

NASDAQ RDNT opened at $70.08 on Monday. The company’s 50 day simple moving average is $71.96 and its two-hundred day simple moving average is $74.02. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.87 and a quick ratio of 1.87. RadNet has a 1 year low of $45.00 and a 1 year high of $85.84. The stock has a market capitalization of $5.41 billion, a PE ratio of -412.21 and a beta of 1.49.

Hedge Funds Weigh In On RadNet

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its stake in shares of RadNet by 24.8% in the second quarter. BNP Paribas Financial Markets now owns 6,992 shares of the medical research company’s stock worth $398,000 after purchasing an additional 1,388 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in RadNet by 683.3% in the 2nd quarter. Canada Pension Plan Investment Board now owns 4,700 shares of the medical research company’s stock worth $267,000 after buying an additional 4,100 shares during the period. AQR Capital Management LLC grew its position in shares of RadNet by 5.4% in the 1st quarter. AQR Capital Management LLC now owns 6,846 shares of the medical research company’s stock worth $340,000 after buying an additional 350 shares during the last quarter. United Services Automobile Association purchased a new position in shares of RadNet during the first quarter valued at approximately $216,000. Finally, Osaic Holdings Inc. increased its stake in shares of RadNet by 8.9% during the fourth quarter. Osaic Holdings Inc. now owns 3,010 shares of the medical research company’s stock valued at $215,000 after buying an additional 245 shares during the period. 77.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RDNT has been the topic of a number of recent analyst reports. UBS Group set a $92.00 price objective on RadNet in a research report on Friday, January 9th. Zacks Research lowered RadNet from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of RadNet in a research report on Monday, December 29th. Finally, Barclays upped their price objective on shares of RadNet from $79.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, RadNet has an average rating of “Moderate Buy” and an average target price of $90.33.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.